Full text

Turn on search term navigation

© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Salivary and mammary gland tumors show morphological similarities and share various characteristics, including frequent overexpression of hormone receptors and female preponderance. Although this may suggest a common etiology, it remains unclear whether patients with a salivary gland tumor carry an increased risk of breast cancer (BC). Our purpose was to determine the risk of BC in women diagnosed with salivary gland carcinoma (SGC) or pleomorphic adenoma (SGPA). BC incidence (invasive and in situ) was assessed in two nationwide cohorts: one comprising 1567 women diagnosed with SGC and one with 2083 women with SGPA. BC incidence was compared with general population rates using standardized incidence ratio (SIR). BC risk was assessed according to age at SGC/SGPA diagnosis, follow‐up time and (for SGC patients) histological subtype. The mean follow‐up was 7.0 years after SGC and 9.9 after SGPA diagnosis. During follow‐up, 52 patients with SGC and 74 patients with SGPA developed BC. The median time to BC was 6 years after SGC and 7 after SGPA. The cumulative risk at 10 years of follow‐up was 3.1% after SGC and 3.5% after SGPA (95% Confidence Interval (95%CI) 2.1%–4.7% and 2.6%–4.6%, respectively). BC incidence was 1.59 times (95%CI 1.19–2.09) higher in the SGC‐cohort than expected based on incidence rates in the general population. SGPA‐patients showed a 1.48 times (95%CI 1.16–1.86) higher incidence. Women with SGC or SGPA have a slightly increased risk of BC. The magnitude of risk justifies raising awareness, but is no reason for BC screening.

Details

Title
Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands
Author
Valstar, Matthijs H 1   VIAFID ORCID Logo  ; Schaapveld, Michael 2 ; Esther C. van den Broek 3 ; Marie‐Louise F. van Velthuysen 4 ; de Ridder, Mischa 5 ; Schmidt, Marjanka K 6 ; Boukje A.C. van Dijk 7 ; Alfons J.M. Balm 1 ; Smeele, Ludi E 1 

 Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Oral and Maxillofacial Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands 
 Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands 
 The Nationwide Network and Registry of Histo‐ and Cytopathology in the Netherlands (PALGA, Houten, The Netherlands 
 Department of Pathology Erasmus Medical Centre, Rotterdam, The Netherlands 
 Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Radiation Oncology, Leiden University Medical Center, University of Leiden, Leiden, The Netherlands 
 Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands 
 Netherlands Comprehensive Cancer Organization (IKNL, Department of Research and Development, Utrecht, The Netherlands; Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands 
Pages
424-434
Section
CANCER PREVENTION
Publication year
2021
Publication date
Jan 2021
Publisher
John Wiley & Sons, Inc.
e-ISSN
20457634
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2480040486
Copyright
© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.